Phaseline

Companies › GeneQuantum Healthcare (Suzhou)

GeneQuantum Healthcare (Suzhou): clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 3; Oncology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
GQ1005
HER2-targeting antibody-drug conjugate
–Phase 3HER2-positive Breast CancerJan 2027
GQ1010–Phase 1Advanced Malignant Solid TumorsMay 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07673029GQ1005Phase 3HER2-positive Breast CancerOncologyJan 2027
NCT06464055GQ1010Phase 1Advanced Malignant Solid TumorsOncologyMay 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

GC Cell Immuneering InxMed (Shanghai) PharmaMar Sellas Life Sciences Group

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.